Abstract:
PROBLEM TO BE SOLVED: To provide novel azaadamantane derivatives.SOLUTION: The invention relates to compounds that are azaadamantane derivatives of formula (I), particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof. In the formula, Ldenotes -O- or -NR-; A denotes -Ar, -Ar-L-Aror -Ar-L-Ar; Ardenotes aryl or heteroaryl; Ardenotes aryl or monocyclic heteroaryl; Ardenotes aryl or heteroaryl; Ardenotes bicyclic heteroaryl; Ardenotes aryl or heteroaryl; Ldenotes a binding, -O -, -NR-, -CH- or -C(O)NR-; L3 denotes a binding, -O-, -NR-or -CH-; and Rdenotes hydrogen or alkyl.
Abstract translation:待解决的问题:提供新的氮杂金刚烷衍生物。 解决方案:本发明涉及式(I)的氮杂金刚烷衍生物,特别是醚或胺取代的氮杂金刚烷衍生物及其盐和前药的化合物。 在该式中,L 1 SB>表示-O-或-NR a SB> - ; A表示-Ar 1 SB>,-Ar 2 SB> -L 2 SB> 3 SB>或-Ar 4 SB> -L 3 SB> -Ar 5 SB>; Ar 1 SB>表示芳基或杂芳基; Ar 2表示芳基或单环杂芳基; Ar 3 SB>表示芳基或杂芳基; Ar 4 SB>表示双环杂芳基; Ar 5 SB>表示芳基或杂芳基; L 2 SB>表示结合,-O - , - NR a SB> - ,-CH 2 SB> - 或-C(O)NR a SB> - ; L3表示结合,-O-,-NR a SB> - 或-CH 2 SB> 并且R a SB>表示氢或烷基。 版权所有(C)2013,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a series of N-substituted diazabicyclic compound, a method for selectively controlling releasing of a synaptic transmission substance in mammals by using the compound, and a pharmaceutical composition including the compound.SOLUTION: The present invention provides a compound expressed by formula (I), a pharmaceutical composition of the compound, and use of the composition to control synaptic transmission in mammals (in a nicotinic acetylcholine receptor ligand). In formula (I), A is selected from a group consisting of CH2, CH2CH2, and the like; B is selected from a group consisting of CH2 and CH2CH2, however, when A is CH2CH2CH2, B is CH2; Y is selected from a group consisting of CH2 and CH2CH2; Z is selected from a group consisting of CH2 and CH2CH2, however, when Y is CH2CH2, Z is a covalent bond, and when Z is CH2CH2, Y is a covalent bond; and Rl is pyridine or the like.
Abstract:
The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
Abstract:
The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
Abstract:
The invention relates to neuronal nicotinic receptor ligands, methods of identifying such ligands for neuronal nicotinic receptor modulation, particularly such ligands demonstrating beneficial side effect tolerability, and methods of using such neuronal nicotinic receptor ligands to provide pharmaceutical compositions and products.
Abstract:
Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N + -O - ; X is O, S, -NH-, and -N-alkyl-; Ar 1 is a 6-membered aromatic ring; and Ar 2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Abstract translation:其中n为0,1或2的式(I)化合物; A是N或N + O - - O - X是O,S,-NH-和-N-烷基 - ; Ar 1是6元芳环; 并且Ar 2是稠合的双环杂环。 该化合物可用于治疗由α7nAChR配体预防或改善的病症或病症。 还公开了具有式(I)化合物的药物组合物和使用这些化合物和组合物的方法。
Abstract:
Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring G1, X, R1, and R2 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.
Abstract:
Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N + -O - ; X is O, S, -NH-, and -N-alkyl-; Ar 1 is a 6-membered aromatic ring; and Ar 2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Abstract:
The present application relates to indole and indoline derivatives of formula (I) wherein a, R1, R2, R3, h, i, j, m, n, L, Q, and X are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions.
Abstract:
The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to a7 nicotinic acetylcholine receptors also are described.